Table 1.
Patient characteristics distributed by treatment arm and BRCA1 classification of the stage III series
| Variable | Patients with non-BRCA1-likeCGH tumours |
Patients with BRCA1-likeCGH tumours |
Pb | |||||||||||||
| Conventional chemotherapy |
HD-PB chemotherapy |
Total |
Pa | Conventional chemotherapy |
HD-PB chemotherapy |
Total |
Pa | |||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||||
| Total | 95 | 50.3 | 94 | 49.7 | 189 | 100.0 | 23 | 56.1 | 18 | 43.9 | 41 | 100.0 | n.s | |||
| Age in categories, years | ||||||||||||||||
| ≤40 | 21 | 22.1 | 22 | 23.4 | 43 | 22.8 | n.s | 11 | 47.8 | 9 | 50.0 | 20 | 48.8 | n.s | 0.002 | |
| >40 | 74 | 77.9 | 72 | 76.6 | 146 | 77.2 | 12 | 52.2 | 9 | 50 | 21 | 51.2 | ||||
| Type of surgery | ||||||||||||||||
| Breast-conserving therapy | 16 | 16.8 | 18 | 19.1 | 34 | 18.0 | n.s | 8 | 34.8 | 6 | 33.3 | 14 | 34.1 | n.s | 0.03 | |
| Mastectomy | 79 | 83.2 | 76 | 80.9 | 155 | 82.0 | 15 | 65.2 | 12 | 66.7 | 27 | 65.9 | ||||
| Pathological tumour classification | ||||||||||||||||
| pT1 or pT2 | 80 | 84.2 | 78 | 83.0 | 158 | 83.6 | n.s | 19 | 82.6 | 17 | 94.4 | 36 | 87.8 | n.s | n.s | |
| pT3 | 15 | 15.8 | 14 | 14.9 | 29 | 15.3 | 4 | 17.4 | 1 | 5.6 | 5 | 12.2 | ||||
| Unknown | 0 | 0.0 | 2 | 2.1 | 2 | 1.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||||
| Number of positive lymph nodes | ||||||||||||||||
| 4–9 | 66 | 69.5 | 59 | 62.8 | 125 | 66.1 | n.s | 15 | 65.2 | 11 | 61.1 | 26 | 63.4 | n.s | n.s | |
| ≥10 | 29 | 30.5 | 35 | 37.2 | 64 | 33.9 | 8 | 34.8 | 7 | 38.9 | 15 | 36.6 | ||||
| Histological grade | ||||||||||||||||
| I + II | 63 | 66.3 | 63 | 67.0 | 126 | 66.7 | n.s | 4 | 17.4 | 1 | 5.6 | 5 | 12.2 | n.s | <0.001 | |
| III | 30 | 31.6 | 27 | 28.7 | 57 | 30.2 | 19 | 82.6 | 14 | 77.8 | 33 | 80.5 | ||||
| Not determined | 2 | 2.1 | 4 | 4.3 | 6 | 3.2 | 0 | 0.0 | 3 | 16.7 | 3 | 7.3 | ||||
| Triple-negative status | ||||||||||||||||
| ER or PR positive (≥10%) | 82 | 86.3 | 81 | 86.2 | 163 | 86.2 | n.s | 4 | 17.4 | 1 | 5.6 | 5 | 12.2 | n.s | <0.001 | |
| Triple negative | 13 | 13.7 | 13 | 13.8 | 26 | 13.8 | 18 | 78.3 | 16 | 88.9 | 34 | 82.9 | ||||
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 4.3 | 1 | 5.6 | 2 | 4.9 | ||||
| Nielsen basal-like breast cancer definition | ||||||||||||||||
| Negative | 89 | 93.7 | 85 | 90.4 | 174 | 92.1 | n.s | 7 | 30.4 | 2 | 11.1 | 9 | 22.0 | n.s | <0.001 | |
| Basal-like | 6 | 6.3 | 9 | 9.6 | 15 | 7.9 | 15 | 65.2 | 15 | 83.3 | 30 | 73.2 | ||||
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 4.3 | 1 | 5.6 | 2 | 4.9 | ||||
| P53 status | ||||||||||||||||
| Negative (<10%) | 51 | 53.7 | 65 | 69.1 | 116 | 61.4 | 0.05 | 8 | 34.8 | 7 | 38.9 | 15 | 36.6 | n.s | 0.02 | |
| Positive (≥10%) | 40 | 42.1 | 26 | 27.7 | 66 | 34.9 | 12 | 52.2 | 8 | 44.4 | 20 | 48.8 | ||||
| Unknown | 4 | 4.2 | 3 | 3.2 | 7 | 3.7 | 3 | 13.0 | 3 | 16.7 | 6 | 14.6 | ||||
Patients with unknown values were omitted and P values were calculated using the Fisher’s exact test.
a
Association within subgroup.
b
Association between subgroups.
CGH, comparative genomic hybridisation; ER, estrogen receptor; n.s., non-significant; PR, progesterone receptor.